# Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use

> **NCT00167973** · — · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 218 (actual)

## Conditions studied

- Hemophilia B

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00167973
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2010-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00167973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00167973, "Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00167973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*